IFRX InflaRx N.V.
$1.73▲ +4.22%
Healthcare
Other
After hours
$1.73▲ +0.00%
Oct 28, 4:00 PM ET
Volume 493.8K
Avg Volume (10D) 910.3K
Key Metrics & Fundamentals
Market Cap
$254.95M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.80 - 2.95
% vs 50 MA
-8.21%
% vs 200 MA
6.12%
RSI-14
54.4
MACD Histogram
+0.0400
Beta (1Y vs SPY)
2.25
Free Cash Flow
-$2.61M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$6.14M
COGS
$0
Operating Exp
$7.00M
Operating Income
-$7.00M
EBIT
-$7.00M
Pretax Income
-$10.60M
Net Income
-$10.65M
EPS (Diluted)
-0.09
Price & Volume History
Loading chart…
Recent News
InflaRx Announces November Investor Events
GlobeNewswire · Oct 27, 2026 7:30 AM ET
InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026
GlobeNewswire · Oct 22, 2026 12:00 PM ET
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
GlobeNewswire · Oct 2, 2026 7:30 AM ET
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
GlobeNewswire · Oct 1, 2026 7:30 AM ET
InflaRx to Host Virtual Capital Markets Day
GlobeNewswire · Sep 21, 2026 7:30 AM ET
Needham Initiates InflaRx at Buy With $8 Price Target
MT Newswires · Sep 14, 2026 6:40 AM ET
InflaRx Announces Participation in September Investor Conferences
GlobeNewswire · Aug 20, 2026 7:30 AM ET
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
GlobeNewswire · Aug 6, 2026 7:30 AM ET
Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates
Zacks · Aug 4, 2026 8:50 AM ET
Financial Overview - Income Statement
Quarterly
Sep 2025
See IFRX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.